Belzutifan

Renal cell carcinoma is a common malignant tumor of the urinary system worldwide. Patients with advanced-stage renal cell carcinoma have a poor prognosis, and there is an urgent clinical need for more precise targeted therapeutic regimens. Belzutifan is a novel hypoxia-inducible factor-2α (HIF-2α) inhibitor. It selectively blocks the binding of HIF-2α to its heterodimer partner HIF-1β, inhibits the expression of downstream genes related to tumor growth promotion and angiogenesis, and disrupts the survival pathway of tumor hypoxia adaptation. Currently, its approved indications include VHL disease-associated renal cell carcinoma, central nervous system hemangioblastoma and pancreatic neuroendocrine tumor, providing a new option for long-term disease control for this specific population without the need for concomitant surgery.

At present, the global belzutifan market is still in a rapid expansion stage. In 2023, its global sales exceeded USD 400 million, with an annual growth rate remaining above 60%. As no generic drug has been approved in China for the time being, the market is still exclusively occupied by the original research product. With the improvement of the diagnosis rate of VHL disease in China and the advancement of the exploration of combination therapy for advanced renal cell carcinoma, it is estimated that the domestic market size will exceed RMB 200 million in the next three years. At present, a number of domestic pharmaceutical companies have arranged for the research and development of generic drugs of this variety, and the core competitive points focus on the optimization of API synthesis process and the compliance control of impurity profile.

The original research enterprise of belzutifan is Merck Sharp & Dohme, and the original research trade name is Welireg. Its core compound patent in the United States expires in 2037, and the compound patent in China expires in 2038. The main dosage form approved by the original research is tablet, with specifications of 20mg, 40mg and 80mg. The original research tablets have been included in the FDA Reference Listed Drug Catalog, but have not been included in the Chinese Chemical Reference Listed Drug Catalog for the time being. There is no belzutifan preparation approved for marketing in China. In terms of API, some enterprises have submitted DMF registration applications, which are all in the status of pending activation for approval. (Data as of June 2025, please refer to the official website of CDE for the latest information)

CATO can provide a full set of belzutifan impurity reference standards, covering process impurities, degradation impurities and enantiomers that may be generated during the synthesis process. All products meet the requirements of Chinese Pharmacopoeia and relevant FDA regulations. Most impurities are available from stock. For in-stock orders, payment before 16:00 can be delivered on the same day, which fully meets the needs of compliance research and quality control in the research and development stage of pharmaceutical companies, and helps enterprises accelerate the progress of application.